Bristol Myers reaches a crossroads as a make-or-break year takes shape
Bristol Myers Squibb enters a pivotal year with multiple late-stage readouts and strategic decisions that could reshape its growth trajectory through the back half of the decade.
Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:Princeton, New Jersey, USA
Founded:1887
Website:www.bms.com/
Recent News
Leadership Team
Christopher Boerner, Ph.D.
Chairman and Chief Executive Officer
David Elkins
Chief Financial Officer
Careers & Job Openings